Artivion logo

ArtivionNYSE: AORT

Profile

Sector:

Healthcare

Country:

United States

IPO:

12 February 1993

Next earnings report:

02 August 2024

Last dividends:

09 December 2015

Next dividends:

N/A
$1.07 B
-4%vs. 3y high
76%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
76%vs. sector
-32%vs. 3y high
46%vs. sector

Price

after hours | Fri, 28 Jun 2024 23:37:02 GMT
$25.65+$1.30(+5.34%)

Dividend

No data over the past 3 years
$97.43 M$97.66 M
$97.43 M$7.53 M

Analysts recommendations

Institutional Ownership

AORT Latest News

Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
Zacks Investment Research06 May 2024 Sentiment: POSITIVE

Artivion (AORT) reported quarterly earnings of $0.06 per share, surpassing the Zacks Consensus Estimate of $0.02 per share. This represents an increase from earnings of $0.02 per share in the same quarter last year.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Zacks Investment Research15 April 2024 Sentiment: POSITIVE

Here is the performance of Artivion (AORT) and Cencora (COR) compared to their sector in the current year.

Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
Zacks Investment Research29 March 2024 Sentiment: POSITIVE

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Are Medical Stocks Lagging Artivion (AORT) This Year?
Zacks Investment Research28 March 2024 Sentiment: NEUTRAL

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

3 Buy-Rated Small Caps Flexing Big Growth
Zacks Investment Research19 March 2024 Sentiment: POSITIVE

Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
Zacks Investment Research14 March 2024 Sentiment: POSITIVE

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research12 March 2024 Sentiment: POSITIVE

Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Zacks Investment Research22 February 2024 Sentiment: POSITIVE

Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
Zacks Investment Research22 February 2024 Sentiment: POSITIVE

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet
Zacks Investment Research21 February 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • 1(current)

What type of business is Artivion?

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

What sector is Artivion in?

Artivion is in the Healthcare sector

What industry is Artivion in?

Artivion is in the Medical Devices industry

What country is Artivion from?

Artivion is headquartered in United States

When did Artivion go public?

Artivion initial public offering (IPO) was on 12 February 1993

What is Artivion website?

https://artivion.com

Is Artivion in the S&P 500?

No, Artivion is not included in the S&P 500 index

Is Artivion in the NASDAQ 100?

No, Artivion is not included in the NASDAQ 100 index

Is Artivion in the Dow Jones?

No, Artivion is not included in the Dow Jones index

When does Artivion report earnings?

The next expected earnings date for Artivion is 02 August 2024